SG11202101486RA - Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation - Google Patents
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparationInfo
- Publication number
- SG11202101486RA SG11202101486RA SG11202101486RA SG11202101486RA SG11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA
- Authority
- SG
- Singapore
- Prior art keywords
- substitued
- imidazo
- amino
- preparation
- improved methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765094P | 2018-08-16 | 2018-08-16 | |
| US201862720970P | 2018-08-22 | 2018-08-22 | |
| PCT/US2019/046594 WO2020037094A1 (en) | 2018-08-16 | 2019-08-15 | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101486RA true SG11202101486RA (en) | 2021-03-30 |
Family
ID=67809671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101486RA SG11202101486RA (en) | 2018-08-16 | 2019-08-15 | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11572360B2 (en) |
| EP (1) | EP3837245A1 (en) |
| JP (1) | JP2021534180A (en) |
| KR (1) | KR20210046022A (en) |
| CN (1) | CN112888677A (en) |
| AU (1) | AU2019321470A1 (en) |
| BR (1) | BR112021002642A2 (en) |
| CA (1) | CA3109778A1 (en) |
| IL (1) | IL280823A (en) |
| MX (1) | MX2021001581A (en) |
| SG (1) | SG11202101486RA (en) |
| WO (1) | WO2020037094A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE922316A1 (en) | 1991-07-17 | 1993-01-27 | Smithkline Beecham Corp | Retroviral protease inhibitors |
| ES2706547T3 (en) | 1998-12-23 | 2019-03-29 | Pfizer | Human monoclonal antibodies for CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| CN101248089A (en) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
| JP5342450B2 (en) | 2006-12-15 | 2013-11-13 | ブリストル−マイヤーズ スクイブ カンパニー | Arylpropionamide, arylacrylamide, arylpropinamide, or arylmethylurea analogs as factor XIa inhibitors |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP2706057B1 (en) | 2008-12-05 | 2016-04-20 | Molecular Insight Pharmaceuticals, Inc. | Bis(imidazolyl)compounds and radionuclide complexes |
| CN104479018B (en) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function |
| KR101740171B1 (en) | 2009-11-24 | 2017-05-25 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
| WO2011150243A1 (en) | 2010-05-28 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| HU1000676D0 (en) | 2010-12-17 | 2011-02-28 | Pharmahungary 2000 Kft | Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved |
| RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
| KR20120122705A (en) | 2011-04-29 | 2012-11-07 | 주식회사 레고켐 바이오사이언스 | Imidazole-based Alkaloid Derivatives for Inhibition of Angiogenesis and anti-oxidant activity, and Methods for Preparing them |
| EA036814B9 (en) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof |
| KR102193343B1 (en) | 2012-05-15 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| LT2996473T (en) | 2013-05-18 | 2019-12-10 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| AR094537A1 (en) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
| CA2932966C (en) | 2013-12-12 | 2022-03-22 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| JP6367366B2 (en) | 2014-04-22 | 2018-08-01 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4-amino-imidazoquinoline compounds |
| WO2016008010A1 (en) | 2014-07-16 | 2016-01-21 | Novogen ltd | Functionalised and substituted carbazoles as anti-cancer agents |
| KR20170083136A (en) | 2014-11-18 | 2017-07-17 | 머크 샤프 앤드 돔 코포레이션 | Aminopyrazine compounds with a2a antagonist properties |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| KR102492532B1 (en) | 2015-05-29 | 2023-01-30 | 아게누스 인코포레이티드 | Anti-CTLA-4 Antibodies and Methods of Using The Same |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (en) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH) |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN111385767A (en) | 2016-02-02 | 2020-07-07 | 华为技术有限公司 | Method for determining transmission power, user equipment and base station |
| US10653681B2 (en) | 2016-03-16 | 2020-05-19 | Recurium Ip Holdings, Llc | Analgesic compounds |
| AU2017252640A1 (en) | 2016-04-19 | 2018-12-06 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| TWI674261B (en) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 modulators |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| ES2930171T3 (en) | 2018-08-16 | 2022-12-07 | Innate Tumor Immunity Inc | Imidazo[4,5-C]quinoline-derived NLRP3 modulators |
| KR20210045430A (en) | 2018-08-16 | 2021-04-26 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Imidazo[4,5-c]quinoline-derived NLRP3-modulator |
-
2019
- 2019-08-15 WO PCT/US2019/046594 patent/WO2020037094A1/en unknown
- 2019-08-15 KR KR1020217007428A patent/KR20210046022A/en unknown
- 2019-08-15 US US17/268,725 patent/US11572360B2/en active Active
- 2019-08-15 BR BR112021002642-8A patent/BR112021002642A2/en not_active Application Discontinuation
- 2019-08-15 CN CN201980067722.XA patent/CN112888677A/en active Pending
- 2019-08-15 CA CA3109778A patent/CA3109778A1/en not_active Abandoned
- 2019-08-15 SG SG11202101486RA patent/SG11202101486RA/en unknown
- 2019-08-15 EP EP19762009.9A patent/EP3837245A1/en not_active Withdrawn
- 2019-08-15 JP JP2021507851A patent/JP2021534180A/en active Pending
- 2019-08-15 AU AU2019321470A patent/AU2019321470A1/en not_active Abandoned
- 2019-08-15 MX MX2021001581A patent/MX2021001581A/en unknown
-
2021
- 2021-02-11 IL IL280823A patent/IL280823A/en unknown
-
2022
- 2022-11-22 US US17/991,875 patent/US11827597B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112888677A (en) | 2021-06-01 |
| KR20210046022A (en) | 2021-04-27 |
| CA3109778A1 (en) | 2020-02-20 |
| MX2021001581A (en) | 2021-04-19 |
| EP3837245A1 (en) | 2021-06-23 |
| BR112021002642A2 (en) | 2021-05-04 |
| JP2021534180A (en) | 2021-12-09 |
| US11827597B2 (en) | 2023-11-28 |
| US20210332040A1 (en) | 2021-10-28 |
| US20230097144A1 (en) | 2023-03-30 |
| US11572360B2 (en) | 2023-02-07 |
| IL280823A (en) | 2021-04-29 |
| WO2020037094A1 (en) | 2020-02-20 |
| AU2019321470A1 (en) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258857A1 (en) | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors | |
| IL290276A (en) | Tetracyclic compound, preparation method and use thereof | |
| EP3439658A4 (en) | SOLUBLE C5aR ANTAGONISTS | |
| IL251164B (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| EP3154970A4 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| HK1255408A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| EP3621613A4 (en) | Aminopyridine compounds and methods for the preparation and use thereof | |
| AU2017435893B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| IL279662A (en) | Methods for the administration of certain vmat2 inhibitors | |
| IL280182A (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
| EP3421038A4 (en) | Naphthyridine compound, pharmaceutical composition and use thereof | |
| SG11202104331YA (en) | Naphthyridine and quinoline derivatives useful as alk5 inhibitors | |
| EP3508483A4 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| EP3752149A4 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
| EP3790864A4 (en) | Quinoline derivatives and preparation methods and uses thereof | |
| IL269214B (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| IL251166A0 (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| EP3808751A4 (en) | Camptothecin derivative, preparation method therefor and application thereof | |
| IL271233A (en) | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation | |
| IL280823A (en) | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | |
| EP3694488A4 (en) | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof | |
| IL269215A (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| EP3302060A4 (en) | Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase | |
| EP3522757A4 (en) | Self-making bedding system, method and kit thereof | |
| EP3666767A4 (en) | Pyridazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof |